Pharma firm Advanz fined after thyroid drug price hike of 6,000% | Pharmaceuticals industry

The UK’s competition watchdog has imposed fines of more than £100m on the pharmaceutical company Advanz and its former private equity owners after it was found to have inflated the price of its thyroid tablets by up to 6,000% . An investigation by the Competition and Markets Authority (CMA) found that the private-equity backed pharmaceutical company charged “excessive and unfair prices” for liothyronine tablets, which are used to treat thyroid hormone deficiency.

Read the source article at theguardian.com
2021-07-30 09:58:19